New drug SPG302 tested for schizophrenia in small trial
NCT ID NCT06442462
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests whether SPG302, a small synthetic molecule, can safely reduce schizophrenia symptoms in adults. 32 participants will receive either the drug or a placebo. Researchers will measure symptom severity, brain activity, and eye tracking to see if the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SPG302 (a small synthetic molecule)
What this could lead to
If successful, this could point toward a new treatment option for schizophrenia symptoms.
What could go wrong
This is a small, early-phase trial with only 32 participants. The drug may not improve symptoms or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Box Hill Hospital - Eastern Health
Box Hill, Victoria, 3128, Australia
-
CenExel CNS
Garden Grove, California, 92845, United States
-
Multidisciplinary Alfred Psychiatry Research Centre (MAPrc)
Melbourne, Victoria, 3004, Australia